Limitations of tissue microarrays compared with whole tissue sections in survival analysis

Khouja,M. Haysam; Baekelandt,Mark; Sarab,Agkha; Nesland,Jahn M.; Holm,Ruth

doi:10.3892/ol_00000145

Limitations of tissue microarrays compared with whole tissue sections in survival analysis

Authors:
- M. Haysam Khouja
- Mark Baekelandt
- Agkha Sarab
- Jahn M. Nesland
- Ruth Holm
View Affiliations

Affiliations: Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital and University of Oslo, Norway
Published online on: September 1, 2010 https://doi.org/10.3892/ol_00000145
Pages: 827-831

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tissue microarray (TMA) is a promising technique in the evaluation of immunohistochemical markers in tumors and may be used as an alternative for whole sections. However, only a few studies have correlated a clinical outcome with both TMA and results obtained from whole sections. This study compared immunostaining for Ki-67 and p16 in TMA (3 cores from each specimen) and whole sections of 171 cases of stage III epithelial ovarian cancer with clinical data. A high expression of Ki-67 was identified in 85.0, 85.5, 85.8, 90.5 and 84% of cores 1, 2 and 3, TMAs and whole tissue sections, respectively. A high p16 expression was found in 36.5, 31.4, 30.3, 46.3 and 31.0% of cores 1, 2 and 3, TMAs and whole tissue sections, respectively. The high expression of Ki-67 and p16 in whole tissue sections significantly correlated with that of Ki-67 and p16 in core 1 (P<0.0001 and P<0.0001, respectively), core 2 (P<0.0001 and P<0.0001, respectively), core 3 (P<0.0001 and P<0.0001, respectively), and TMAs (P<0.0001 and P<0.0001, respectively). In univariate analysis, a high expression of Ki-67 and p16 in two of the cores; TMA and the whole tissue sections were significantly correlated to disease-related survival (Ki-67: P=0.008, 0.012, 0.012 and 0.0001, respectively, and p16: P=0.0007, 0.0005, 0.0008 and 0.005, respectively). However, in the multivariate analysis only Ki-67 on whole tissue sections retained an independent prognostic significance (P=0.025). We concluded that more studies, with a higher number of cores, are necessary to determine the efficacy of TMA in reflecting the prognostic value of different antibodies. Morever, evaluation of this method is crucial for each type of tumor and each separate antigen. It is also essential to confirm the clinical correlations on the whole sections before investigating the same parameters on TMA.

View Figures

View References

1	Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G and Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 4:844–847. 1998. View Article : Google Scholar : PubMed/NCBI
2	Mills SE, Fechner RE, Frierson HF, Kempson RL, Wick MR, Dehner LP, Swanson PE and Humphrey PA: Guardians of the wax and the patient. Am J Clin Pathol. 104:365–367. 1995.PubMed/NCBI
3	Camp RL, Charette LA and Rimm DL: Validation of tissue microarray technology in breast carcinoma. Lab Invest. 80:1943–1949. 2000. View Article : Google Scholar : PubMed/NCBI
4	Tolgay OI, Dolled-Filhart M, D’Aquila TG, Camp RL and Rimm DL: Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors. Cancer. 97:1841–1848. 2003. View Article : Google Scholar
5	Korsching E, Packeisen J, Agelopoulos K, Eisenacher M, Voss R, Isola J, van Diest PJ, Brandt B, Boecker W and Buerger H: Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest. 82:1525–1533. 2002. View Article : Google Scholar
6	Griffin MC, Robinson RA and Trask DK: Validation of tissue microarrays using p53 immunohistochemical studies of squamous cell carcinoma of the larynx. Mod Pathol. 16:1181–1188. 2003. View Article : Google Scholar : PubMed/NCBI
7	Kuwabara S, Ajioka Y, Watanabe H, Hitomi J, Nishikura K and Hatakeyama K: Heterogeneity of p53 mutational status in esophageal squamous cell carcinoma. Jpn J Cancer Res. 89:405–410. 1998. View Article : Google Scholar : PubMed/NCBI
8	Baisse B, Bouzourene H, Saraga EP, Bosman FT and Benhattar J: Intratumor genetic heterogeneity in advanced human colorectal adenocarcinoma. Int J Cancer. 93:346–352. 2001. View Article : Google Scholar : PubMed/NCBI
9	Jourdan F, Sebbagh N, Comperat E, Mourra N, Flahault A, Olschwang S, Duval A, Hamelin R and Flejou JF: Tissue microarray technology: validation in colorectal carcinoma and analysis of p53, hMLH1, and hMSH2 immunohistochemical expression. Virchows Arch. 443:115–121. 2003. View Article : Google Scholar : PubMed/NCBI
10	Gomaa W, Ke Y, Fujii H and Helliwell T: Tissue microarray of head and neck squamous carcinoma: validation of the methodology for the study of cutaneous fatty acid-binding protein, vascular endothelial growth factor, involucrin and Ki-67. Virchows Arch. 447:701–709. 2005. View Article : Google Scholar
11	Rosen DG, Huang X, Deavers MT, Malpica A, Silva EG and Liu J: Validation of tissue microarray technology in ovarian carcinoma. Mod Pathol. 17:790–797. 2004. View Article : Google Scholar : PubMed/NCBI
12	Nocito A, Bubendorf L, Tinner EM, et al: Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol. 194:349–357. 2001. View Article : Google Scholar : PubMed/NCBI
13	Merseburger AS, Kuczyk MA, Serth J, et al: Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues. Oncol Rep. 10:223–228. 2003.
14	Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Kochli OR, Mross F, Dieterich H, Moch H, Mihatsch M, Kallioniemi OP and Sauter G: Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol. 159:2249–2256. 2001. View Article : Google Scholar : PubMed/NCBI
15	Khouja MH, Baekelandt M, Nesland JM and Holm R: The clinical importance of Ki-67, p16, p14, and p57 expression in patients with advanced ovarian carcinoma. Int J Gynecol Pathol. 26:418–425. 2007. View Article : Google Scholar : PubMed/NCBI
16	Kaplan EL and Meier P: Nonparametric estimation from incomplete observation. J Am Stat Assoc. 53:457–481. 1958. View Article : Google Scholar
17	Cox DR: Regression models and life tables. J R Stat Soc B. 34:187–220. 1972.
18	Sapino A, Marchio C, Senetta R, Castellano I, Macri L, Cassoni P, Ghisolfi G, Cerrato M, D’Ambrosio E and Bussolati G: Routine assessment of prognostic factors in breast cancer using a multicore tissue microarray procedure. Virchows Arch. 449:288–296. 2006. View Article : Google Scholar : PubMed/NCBI
19	Su Y, Shrubsole MJ, Ness RM, Cai Q, Kataoka N, Washington K and Zheng W: Immunohistochemical expressions of Ki-67, cyclin D1, beta-catenin, cyclooxygenase-2, and epidermal growth factor receptor in human colorectal adenoma: a validation study of tissue microarrays. Cancer Epidemiol Biomarkers Prev. 15:1719–1726. 2006. View Article : Google Scholar
20	Leversha MA, Fielding P, Watson S, Gosney JR and Field JK: Expression of p53, pRB, and p16 in lung tumours: a validation study on tissue microarrays. J Pathol. 200:610–619. 2003. View Article : Google Scholar : PubMed/NCBI
21	Tawfik El-Mansi M and Williams AR: Validation of tissue microarray technology using cervical adenocarcinoma and its precursors as a model system. Int J Gynecol Cancer. 16:1225–1233. 2006.PubMed/NCBI
22	Kallioniemi OP, Wagner U, Kononen J and Sauter G: Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet. 10:657–662. 2001. View Article : Google Scholar : PubMed/NCBI
23	Fernebro E, Dictor M, Bendahl PO, Ferno M and Nilbert M: Evaluation of the tissue microarray technique for immunohistochemical analysis in rectal cancer. Arch Pathol Lab Med. 126:702–705. 2002.PubMed/NCBI
24	Fons G, Hasibuan SM, van der Velden J and ten Kate FJ: Validation of tissue microarray technology in endometrioid cancer of the endometrium. J Clin Pathol. 60:500–503. 2007. View Article : Google Scholar : PubMed/NCBI
25	Zerkowski MP, Camp RL, Burtness BA, Rimm DL and Chung GG: Quantitative analysis of breast cancer tissue microarrays shows high cox-2 expression is associated with poor outcome. Cancer Invest. 25:19–26. 2007. View Article : Google Scholar : PubMed/NCBI